The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.

Inclusion Criteria:

• Presence of signs and symptoms of ocular inflammation in both eyes.
• Have a positive CAC response at Visit 1.
• Able to avoid the use of disallowed medications as well as contact lens wear for the specified period prior to Visit 1, and for the duration of the study.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Have known history or presence of persistent dry eye syndrome.
• Presence of any ophthalmic abnormality that may affect the study outcomes.
• Have a history of moderate to severe allergic asthma reaction to mountain cedar or the perennial allergens used in the study.
• Other protocol-defined exclusion criteria may apply.